JP2007517049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517049A5 JP2007517049A5 JP2006547469A JP2006547469A JP2007517049A5 JP 2007517049 A5 JP2007517049 A5 JP 2007517049A5 JP 2006547469 A JP2006547469 A JP 2006547469A JP 2006547469 A JP2006547469 A JP 2006547469A JP 2007517049 A5 JP2007517049 A5 JP 2007517049A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- pharmacological substance
- pharmacological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 23
- 230000000144 pharmacologic effect Effects 0.000 claims 19
- 239000000126 substance Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000000306 recurrent effect Effects 0.000 claims 9
- 230000009429 distress Effects 0.000 claims 8
- 239000002831 pharmacologic agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 229960001158 nortriptyline Drugs 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- CBIAWPMZSFFRGN-UHFFFAOYSA-N Indiplon Chemical compound CC(=O)N(C)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C(=O)C=2SC=CC=2)=C1 CBIAWPMZSFFRGN-UHFFFAOYSA-N 0.000 claims 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 229960004538 alprazolam Drugs 0.000 claims 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960002430 atomoxetine Drugs 0.000 claims 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- FFHBJDQSGDNCIV-MFVUMRCOSA-N bremelanotide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(O)=O)C1=CC=CC=C1 FFHBJDQSGDNCIV-MFVUMRCOSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960000632 dexamfetamine Drugs 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 229960001578 eszopiclone Drugs 0.000 claims 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960003528 flurazepam Drugs 0.000 claims 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 229950003867 indiplon Drugs 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- 229960001344 methylphenidate Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims 1
- 229960004535 oxazepam Drugs 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 229960000835 tadalafil Drugs 0.000 claims 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 1
- 229960003188 temazepam Drugs 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims 1
- 229960003386 triazolam Drugs 0.000 claims 1
- 229960002381 vardenafil Drugs 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 claims 1
- 229960004010 zaleplon Drugs 0.000 claims 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims 1
- 229960001475 zolpidem Drugs 0.000 claims 1
- 229960000820 zopiclone Drugs 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000000575 glycinergic effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53300303P | 2003-12-29 | 2003-12-29 | |
| US62525304P | 2004-11-05 | 2004-11-05 | |
| PCT/US2004/043628 WO2005065308A2 (en) | 2003-12-29 | 2004-12-29 | Compositions and methods to treat recurrent medical conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517049A JP2007517049A (ja) | 2007-06-28 |
| JP2007517049A5 true JP2007517049A5 (enExample) | 2008-02-21 |
Family
ID=34752985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547469A Pending JP2007517049A (ja) | 2003-12-29 | 2004-12-29 | 再発性病状を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7846913B2 (enExample) |
| EP (1) | EP1703907A4 (enExample) |
| JP (1) | JP2007517049A (enExample) |
| KR (1) | KR20070007276A (enExample) |
| AU (1) | AU2004311869A1 (enExample) |
| CA (1) | CA2592631A1 (enExample) |
| RU (1) | RU2006127475A (enExample) |
| WO (1) | WO2005065308A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1383465B1 (en) * | 2001-03-29 | 2011-08-10 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with d-cycloserine |
| US20050209317A1 (en) * | 2004-03-22 | 2005-09-22 | Apkarian A V | Method and compositions for treatment of chronic neuropathic pain |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| MX2007009915A (es) * | 2005-02-15 | 2007-11-06 | Elan Pharma Int Ltd | Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada. |
| DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
| EP1906925A1 (en) * | 2005-07-28 | 2008-04-09 | Teikoku Pharma USA, Inc. | Gelled donepezil compositions and methods for making and using the same |
| BRPI0615972A2 (pt) | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto |
| KR101140110B1 (ko) * | 2006-07-07 | 2012-06-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물 |
| WO2008124814A2 (en) * | 2007-04-10 | 2008-10-16 | Mcdevitt Jason P | Sublingual formulations of d-cycloserine and methods of using same |
| ATE515259T1 (de) * | 2007-05-29 | 2011-07-15 | Lek Pharmaceuticals | Pharmazeutische zusammensetzung mit eszopiclon |
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| US20100291225A1 (en) * | 2008-01-14 | 2010-11-18 | Jubilant Organosys Ltd. | Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same |
| US20100204291A1 (en) * | 2009-02-12 | 2010-08-12 | Mcdevitt Jason P | Method for Facilitating Extinction Training Using D-Cycloserine |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2670409B1 (en) * | 2011-01-31 | 2018-04-18 | Serotech, LLC | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX336979B (es) * | 2011-12-16 | 2016-02-09 | Senosiain S A De C V Lab | Combinacion farmaceutica antineuritica y composiciones. |
| US9877951B2 (en) | 2015-02-12 | 2018-01-30 | College Of William And Mary | Method for treating dementia |
| US20170143681A1 (en) | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| US10485790B1 (en) * | 2018-09-13 | 2019-11-26 | Syneurx International (Taiwan) Corp. | Salts of cycloserine compounds and applications thereof |
| WO2025173704A1 (ja) * | 2024-02-16 | 2025-08-21 | エフバイタル株式会社 | 薬剤のスクリーニング方法、および剤 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| JPH03236315A (ja) * | 1989-12-05 | 1991-10-22 | Nippon Oil & Fats Co Ltd | 抗精神病薬 |
| US5260324A (en) | 1990-02-06 | 1993-11-09 | G. D. Searle & Company | Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5428069A (en) | 1993-01-11 | 1995-06-27 | The United States Of America As Represented By The Department Of Health & Human Services | Treating cognition with, aminocyclopropanecarboxylic derivatives |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US6355681B2 (en) | 1995-12-07 | 2002-03-12 | Glytech, Inc. | Glycine substitutes and precursors for treating a psychosis |
| US6133281A (en) * | 1996-10-24 | 2000-10-17 | Harbor-Ucla Research And Education Institute | NMDA receptor blockers in the therapy of urogenital disease |
| WO1999051252A1 (en) * | 1998-04-03 | 1999-10-14 | The Daily Wellness Company | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
| DE69936848T2 (de) | 1998-04-14 | 2008-05-15 | The General Hospital Corp., Boston | Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| MXPA01010933A (es) * | 1999-04-29 | 2002-06-21 | Merck Patent Gmbh | Inhibidores del sistema de clivaje de la glicina como potenciales antipsicoticos. |
| US20010053780A1 (en) * | 1999-04-30 | 2001-12-20 | Whitaker John S. | Daily treatment for erectile dysfunction using a PDE5 inhibitor |
| US6333357B1 (en) | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| US20050096396A1 (en) | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| EP1383465B1 (en) | 2001-03-29 | 2011-08-10 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with d-cycloserine |
| GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
| EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
-
2004
- 2004-12-29 CA CA002592631A patent/CA2592631A1/en not_active Abandoned
- 2004-12-29 AU AU2004311869A patent/AU2004311869A1/en not_active Abandoned
- 2004-12-29 EP EP04815650A patent/EP1703907A4/en not_active Withdrawn
- 2004-12-29 RU RU2006127475/14A patent/RU2006127475A/ru not_active Application Discontinuation
- 2004-12-29 KR KR1020067015406A patent/KR20070007276A/ko not_active Withdrawn
- 2004-12-29 WO PCT/US2004/043628 patent/WO2005065308A2/en not_active Ceased
- 2004-12-29 JP JP2006547469A patent/JP2007517049A/ja active Pending
- 2004-12-29 US US11/024,921 patent/US7846913B2/en not_active Expired - Fee Related
-
2010
- 2010-11-30 US US12/956,769 patent/US8309535B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517049A5 (enExample) | ||
| Gonda et al. | Novel antidepressant drugs: Beyond monoamine targets | |
| JP7226839B2 (ja) | ブプロピオンおよびデキストロメトルファンを含む組成物 | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| US10682354B2 (en) | Compositions and methods | |
| JP2020023543A (ja) | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 | |
| WO2010129864A3 (en) | Methods and compositions for studying, imaging, and treating pain | |
| CA3094580C (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| RU2006127475A (ru) | Композиции и способы лечения рецидивирующих медицинских состояний | |
| WO2004087116A3 (es) | Combinación de drogas para la disfunción motora en la enfermedad de parkinson | |
| JP2002505681A (ja) | 健常人における気分障害を調節するための組成物 | |
| van Praag et al. | 5-hydroxytryptophan in combination with clomipramine in “therapy-resistant” depressions | |
| NO20082672L (no) | Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon | |
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| MX2008015887A (es) | Tratamiento de condiciones psicologicas utilizando antagonista m1 de receptor muscarinico. | |
| Dorevitch et al. | Fluvoxamine-associated sexual dysfunction | |
| AU783516B2 (en) | Methods, kits and compositions for using pyrrole derivatives | |
| CN103635190A (zh) | 治疗方案 | |
| CN102274268A (zh) | 一种具有戒酒作用的中药活性提取物、其制备方法和应用 | |
| Praag et al. | 5-Hydroxytryptophan in combination with clomipramine in “therapy-resistant” depressions | |
| CN101472571B (zh) | 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用 | |
| CN119837862A (zh) | 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途 | |
| EP4117676A1 (fr) | Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes | |
| Ille et al. | “Add-on”-therapy with an individualized preparation consisting of free amino acids for patients with a major depression | |
| HK40033382A (en) | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |